Sanofi Stock News

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

Sanofi and GlaxoSmithKline are seeking regulatory approval for their Covid-19 vaccine to be used as a booster, as well as a standalone two-dose shot.

French pharmaceuticals giant Sanofi said Wednesday that its Covid-19 vaccine, developed with Britains GSK, had delivered positive results after nearly a year of delays left it lagging far behind rivals in the race for a jab. The two drugmakers said in a statement they will seek regulatory authoris ..

French multinational healthcare company Sanofi S.A. and British GlaxoSmithKline plc (GSK) shared on Wednesday that they will be seeking "regulatory authorization for [our] COVID-19 vaccine."

Sanofi (SNY) and GlaxoSmithKline (GSK) are planning to seek regulatory authorization for a COVID-19 vaccine.The companies intend to submit data from their booster and phase 3

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend

Sanofi India and Gammon India are the companies that will announce their earnings for quarter ended on December 31, 2021.

Sanofi''s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors Paris, February 22, 2022 . At its meeting on February 22, 2022, Sanofi''s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on May 3, 2022, the renewal of the mandates of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors. Melanie Lee and Carole Piwnica will leave the Board of Directors. The Chairman thanked Carole Piwnica for her contribution to the transformation of the group during her almost 12 years in office, and Melanie Lee for her contribution to the scientific reorientation of the group and the creation of the Scientific Committee. Carole Ferrand is currently Chief Financial Officer of the Capgemini Group and Director of Fnac Darty. She began her career in 1992 at PricewaterhouseCoopers where she worked as an auditor and then a financial advisor.

The Conjugate Vaccine Market research report provides an in-depth overview of the industry including market segmentation by product, technology, vertical and geography. Analysis of the global market with special focus on high growth application in each vertical and fast-growing application

Sanofi found using ticker (SNY) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. With the stocks previous close at 52.87 this would indicate that there is a potential upside of 20.4%. The 50 day moving average now sits at 51.1 and the 200 moving average now moves to 50.97. The company has a market cap of $132,438m. Find out more information at: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $159,391m based on the market concensus. Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

GlaxoSmithKline is pausing trials of an respiratory syncytial virus vaccine in pregnant women. Sanofi is halting a trial of its drug Dupixent as a treatment…

Dublin, Feb. 18, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplantation Market (2021-2026) by Treatment, Organ, Product, Transplant, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Organ Transplantation Market is estimated to be USD 12.95 Bn in 2021 and is expected to reach USD 22.1 Bn by 2026, growing at a CAGR of 11.28%. Market Dynamics Factors for Driving the market are demand for tissue and organ plantation is high for organ failure treatment. Organ failure occurs due to various factors such as frivolous trauma, loss of blood, poisoning, drug abuse, etc. The increasing prevalence of renal disease, overconsumption of alcohol, and unhealthy diet have provided a push for the growth of the Organ Transplantation market. Huge population suffering from chronic illness and organ failure. Treatment of failure contributing to the development and Technological advancement and increasing issue banks are also boosting the market.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios''s Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO ) said the U.S. Food and Drug Administration has approved its Pyrukynd (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia, or an accelerated destruction of red blood cells. The company said it expects the treatment to be made available in the U.S. two weeks after the approval. The stock was up 2.95% to $30.33 in premarket trading. Click here to access Benzinga''s FDA Calendar Regeneron, Sanofi Halt Late-Stage Study Of Dupixent In Treating Skin Rash Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi (NASDAQ: SNY ) announced a Phase 3 trial evaluating their co-developed Dupixent in patients with chronic spontaneous urticaria will stop due to futility, based on a pre-specified interim analysis. The trial, which assessed Dupixent added to antihistamines in patients refractory to omalizumab at 24 weeks, showed positive numerical trends in reducing itch and hives but didn''t meet statistical …